GKT137831: Completed Phase II enrollment

Genkyotex completed enrollment of 155 patients in a double-blind, placebo-controlled, international Phase II trial evaluating 100 mg oral GKT137831 twice daily for 6 weeks followed by a 200 mg dose tw...